For people who already have heart disease, adding evolocumab to their cholesterol medicine lowers their risk of heart attack, stroke, or dying from heart problems by about 1 in 5, and the protection gets stronger the longer they take it.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study shows that adding evolocumab to statins helps prevent heart attacks, strokes, and heart-related deaths in high-risk patients, especially over time and in those who’ve had prior heart problems—just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Provide the most precise estimate of evolocumab’s effect on MACE by pooling data from all relevant RCTs.
A systematic review and meta-analysis of all placebo-controlled RCTs of PCSK9 inhibitors in ASCVD patients, pooling time-to-event data for MACE (CV death, MI, stroke) with subgroup analyses by baseline risk, LDL-C reduction, and treatment duration, including at least 3 trials and 40,000 patients.
Establish causal relationship between evolocumab and reduced MACE risk.
A double-blind, placebo-controlled RCT of 30,000 ASCVD patients on statins, randomized to evolocumab 420 mg monthly vs placebo, followed for a median of 3 years for the primary endpoint of first occurrence of CV death, MI, or stroke, with blinded adjudication.
Validate real-world effectiveness and long-term safety of evolocumab on hard outcomes.
A prospective, multinational cohort study of 50,000 ASCVD patients prescribed evolocumab vs matched controls on high-intensity statin alone, using electronic health records to track MACE and mortality over 5 years, adjusting for confounders.